Nilotinib HCI Dihydrate*
-
API Product :
Nilotinib HCI Dihydrate*
-
CEP :
-
-
WCC :
?
-
Therapeutic Use :
Tyrosine Kinase Inhibitor(TKI)
-
Originator :
Inhibikase Therapeutics
-
CAS No. :
641571-10-0
-
Trade Name. :
Tasigna
-
Molecular Weight :
529.5245 g/mol
-
Molecular Formula :
C28H22F3N7O
Application
Nilotinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Nilotinib is used to treat a type of blood cancer called Philadelphia chromosome positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old.
General Description
Nilotinib (AMN107, trade name Tasigna[2]), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.[3] Structurally related to imatinib,[4] it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance.[5][6][7] Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor[5][6] that is 10–30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.[4][6][7][8] Nilotinib was developed by Novartis and is sold under the trade name Tasigna.